This collection of soft-tissue sarcoma dynamic contrast-enhanced (DCE) MRI data contains images from a longitudinal study to assess soft-tissue sarcoma response to preoperative chemoradiation treatment. Images were acquired at three time points: prior to the start of treatment (Visit 1, V1), after the first cycle of chemotherapy (Visit 2, V2), and after ~ 8 more weeks of chemoradiation (prior to surgery) (Visit 3, V3). Not every patient was able to complete all three MRI studies. The value of this collection is to provide clinical imaging data for the development and validation of quantitative imaging methods for assessment of soft-tissue sarcoma response to preoperative treatment. Initial findings of this study have been published and the data is provided by Oregon Health & Science University, PI Dr. Wei Huang. The MRI data consist of DCE-MRI images only, which were acquired using a Siemens 3T TIM Trio system with the body coil as the transmitter and a body matrix phased array (combined with a spine matrix phased array) coil as the receiver. Following scout and axial T2-weighted MRI, a RF-spoiled gradient-echo sequence was used to acquire sagittal DCE-MRI images covering the entire tumor, with 100 flip angle, TE/TR = 1.5/6.0 ms, 24-26 cm field of view (FOV), and 5 mm slice thickness with 1 mm gap. A parallel imaging acceleration factor of 2 was used for DCE-MRI, resulting in 7-16 s temporal resolutions depending on tumor size. The total DCE acquisition time was approximately 10 min with gadolinium contrast agent (Prohance®) IV injection (0.1 mmol/kg at 2 mL/s) carried out following acquisition of five baseline image volumes, followed by a 20-mL saline flush.